Trump Administration to Fund New Research into Psychedelic Drug Ibogaine
The Trump administration will fund new research into the controversial psychedelic drug ibogaine.
Charlottesville, VA, November 12, 2026 — The Trump administration has announced plans to fund new research into the psychedelic drug ibogaine. Ibogaine is a substance that has generated significant attention due to its controversial nature and potential therapeutic applications.
The decision to allocate federal funds for research into ibogaine marks a notable step in the exploration of psychedelic compounds for medical purposes. Ibogaine, a psychoactive alkaloid derived from the West African iboga plant, has been studied for its potential in treating substance use disorders, particularly opioid addiction. However, its use is associated with significant risks, including potential cardiac toxicity, which contributes to its controversial status and regulatory challenges in many regions.
Details regarding the specific scope of the research, the allocated funding amounts, or the institutions selected to conduct the studies were not immediately available. The timeframe for the commencement of this new research initiative also remains unspecified.
The controversial nature of ibogaine stems from both its potent psychoactive effects and its complex legal standing. While proponents highlight anecdotal and preliminary scientific evidence suggesting its efficacy in disrupting addiction cycles, medical professionals and regulatory bodies often express caution due to the drug’s safety profile and the need for controlled administration settings. Further research is considered crucial to better understand its mechanisms of action, efficacy, and safety parameters.
Story summarized from the original created by By MATTHEW PERRONE – AP Health Writer on www.cbs19news.com, see more information here.
Media gallery
